OPPM
NVAX icon

Opus Point Partners Management’s Novavax NVAX Stock Holding History

Opus Point Partners Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,000
Closed -$839K – 59
2015
Q4 		$839K Hold
5,000
– – 0.55% 47
2015
Q3 		$707K Buy
+5,000
New +$1.12M 0.39% 39

Other funds holding NVAX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
QIM
Quantitative Investment Management Charlottesville, Virginia $917M AUM 3.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Opus Point Partners Management's NVAX Position: Q4 2016 in Review

Opus Point Partners Management sold out of Novavax (NVAX) in Q4 2016, closing a stake of 1,289 shares — an estimated $54K sold.

Opus Point Partners Management first reported a position in NVAX in Q2 2016 and held it in 2 quarters. The position peaked at $212K in Q2 2016. 143 funds tracked by Wall St. Rank hold NVAX as of Q4 2016.

  • Opus Point Partners Management reported no remaining Novavax position as of Q4 2016 after selling out during the quarter.
  • Opus Point Partners Management sold 1,289 Novavax shares in Q4 2016, an estimated $54K.
  • Opus Point Partners Management first reported a position in Novavax in Q2 2016 and held it in 2 quarters.
  • Opus Point Partners Management's Novavax position peaked at $212K in Q2 2016.
  • 143 funds tracked by Wall St. Rank held Novavax as of Q4 2016.

Based on Opus Point Partners Management's 13F filing for Q4 2016, filed 14 Feb 2017.